ClinicalTrials.gg

Program

CSL300

A development code.

Its studies are mostly in Kidney Failure, Chronic, led by CSL.

Furthest: phase 3, since Jul 29, 20222 company-led studies, 2 open or runningNext primary completion: Aug 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSL22 open or runningphase 3since Jul 29, 2022Jul 29, 2022Aug 30, 2027phase 1 · NCT07619820

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 29, 2022First study: phase 3 study in Kidney Failure, ChronicFirst studyNCT05485961 · 3,110 planned · United States, Argentina, Australia and more
  2. May 26, 2026Phase 1 study in Kidney Failure, ChronicNCT07619820 · 24 planned · China

Ahead

  1. Aug 30, 2027Primary completion: phase 1 study in Kidney Failure, ChronicNCT07619820
  2. May 22, 2029Primary completion: phase 3 study in Kidney Failure, ChronicNCT05485961

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07619820Kidney Failure, Chronic · China1RecruitingAug 30, 202724
NCT05485961Kidney Failure, Chronic · United States, Argentina, Australia and more3RecruitingMay 22, 20293,110

How it is read

Names in the registry

  • “CSL300”, 2 entries

Codes read as this program: CSL300.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.